组蛋白去乙酰化酶(HDAC)抑制剂ACY241增强抗原特异性中枢记忆性细胞毒性T淋巴细胞对多发性骨髓瘤和实体瘤的抗肿瘤活性
本研究探讨HDAC6选择性抑制剂ACY241对多发性骨髓瘤(MM)患者免疫微环境及抗原特异性细胞毒性T淋巴细胞(CTL)的影响。ACY241可降低CD138+ MM细胞、调节性T细胞及髓源性抑制细胞频率,下调PD1/PD-L1与免疫检查点表达,并增强抗原特异性中枢记忆性CTL的抗肿瘤活性,机制涉及AKT/mTOR/p65通路激活及Bcl-6、Eomes、HIF-1和T-bet上调。
要点
- ACY241降低MM患者CD138+ MM细胞、CD4+CD25+FoxP3+调节性T细胞及HLA-DRLow/-CD11b+CD33+髓源性抑制细胞频率。
- ACY241下调CD8+ T细胞PD1/PD-L1及骨髓细胞免疫检查点表达,上调肿瘤与树突状细胞B7和MHC分子表达。
- ACY241以剂量和时间依赖方式增强抗原特异性中枢记忆性CTL的共刺激分子表达及抗肿瘤活性。
核心结论
- ACY241通过激活AKT/mTOR/p65通路及上调Bcl-6、Eomes、HIF-1和T-bet等转录调节因子增强免疫应答,为单用或联合恢复宿主抗肿瘤免疫提供依据。
研究设计与样本
- 本研究为体外研究,评估HDAC6选择性抑制剂ACY241对多发性骨髓瘤患者骨髓样本及抗原特异性CTL的作用。
主要发现
- ACY241显著降低CD138+ MM细胞、CD4+CD25+FoxP3+调节性T细胞及HLA-DRLow/-CD11b+CD33+髓源性抑制细胞频率。
- ACY241降低CD8+ T细胞PD1/PD-L1表达及骨髓细胞免疫检查点表达,增加肿瘤与树突状细胞B7(CD80、CD86)和MHC(I类、II类)表达。
- ACY241以剂量和时间依赖方式诱导CD28、41BB、CD40L、OX40及CD38表达,并增加穿孔素/CD107a表达、IFN-γ/IL-2/TNF-α产生及抗原特异性中枢记忆性CTL。
- 上述效应与AKT/mTOR/p65通路激活及Bcl-6、Eomes、HIF-1和T-bet上调相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Histone deacetylases (HDAC) are therapeutic targets in multiple cancers. ACY241, an HDAC6 selective inhibitor, has shown anti-multiple myeloma (MM) activity in combination with immunomodulatory drugs and proteasome inhibitors. Here we show ACY241 significantly reduces the frequency of CD138+ MM cells, CD4+CD25+FoxP3+ regulatory T cells, and HLA-DRLow/-CD11b+CD33+ myeloid-derived suppressor cells; and decreases expression of PD1/PD-L1 on CD8+ T cells and of immune checkpoints in bone marrow cells from myeloma patients. ACY241 increased B7 (CD80, CD86) and MHC (Class I, Class II) expression on tumor and dendritic cells. We further evaluated the effect of ACY241 on antigen-specific cytotoxic T lymphocytes (CTL) generated with heteroclitic XBP1unspliced184-192 (YISPWILAV) and XBP1spliced367-375 (YLFPQLISV) peptides. ACY241 induces co-stimulatory (CD28, 41BB, CD40L, OX40) and activation (CD38) molecule expression in a dose- and time-dependent manner, and anti-tumor activities, evidenced by increased perforin/CD107a expression, IFN-γ/IL-2/TNF-α production, and antigen-specific central memory CTL. These effects of ACY241 on antigen-specific memory T cells were associated with activation of downstream AKT/mTOR/p65 pathways and upregulation of transcription regulators including Bcl-6, Eomes, HIF-1 and T-bet. These studies therefore demonstrate mechanisms whereby ACY241 augments immune response, providing the rationale for its use, alone and in combination, to restore host anti-tumor immunity and improve patient outcome.
引用
- Bae J, Hideshima T, Tai YT, et al. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018. PMID: 29487385. doi:10.1038/s41375-018-0062-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。